Title: Method for Treating Cancer Using Interference RNA
Number: 20090148535
Filed: Dec. 8, 2008
Inventor: Cynthia Bamdad, Minerva Biotechnologies
The patent application, its abstract states, claims an "acolloidal nanoparticle that includes a therapeutic nucleic acid species [such as an siRNA] and a targeting protein species attached via a coating on the nanoparticle that facilitates the specific attachment of both species."
Title: Application of RNA Interference Targeting DHFR Gene to Cell for Protein Production
Number: 20090148935
Filed: June 5, 2007
Lead Inventor: Suh-Chin Wu, National Tsing Hua University
The patent application, its abstract states, claims biological materials that can be applied to a Chinese hamster ovary cell "or the like for producing a species of protein."
These biological materials include two vectors, the first of which includes mammalian DHFR and protein genes, and the second of which includes "a DNA fragment for inducing … RNA interference in the CHO cell to reduce expression of a DHFR gene of relevance in [the] CHO cell after the second vector is applied to the CHO cell."
Title: Cell Type-Specific Aptamer-siRNA Delivery System for HIV-1 Therapy
Number: 20090148944
Filed: Dec. 5, 2008
Lead Inventor: John Rossi, City of Hope
The invention "relates to compositions and methods for delivery of siRNA to specific cells or tissue," the patent application's abstract states. "More particularly, the … invention relates to compositions and methods for cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer."
Title: Pharmaceutical Composition for Treating Cancer or Diabetes
Number: 20090149402
Filed: Nov. 15, 2005 PCT Filed: Nov. 15, 2005
Lead Inventor: Taeko Miyagi, Miyagi Cancer Center Research Institute
The patent application, its abstract states, claims "a pharmaceutical composition for treating cancer or diabetes [that] contains [a] double-stranded RNA [of a specific sequence listed in the application or] … a double-stranded RNA which has a sequence of 20 to 30 nucleotides that is identical to a partial sequence of a gene encoding human plasma membrane-associated sialidase."
These dsRNAs, the abstract notes, inhibit the expression of a gene encoding human plasma membrane-associated sialidase.
Title: siRNA Silencing of Genes Expressed in Cancer
Number: 20090149403
Filed: May 29, 2007
Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics (Tekmira Pharmaceuticals)
According to the patent application's abstract, the invention "provides nucleic acid-lipid particles comprising siRNA molecules that silence genes expressed in cancer [such as] Eg5, EGFR, or XIAP, and methods of using such nucleic acid-lipid particles to silence Eg5, EGFR, or XIAP gene expression."
Title: RNA Interference-Mediated Treatment of Alzheimer's Disease Using Short Interfering Nucleic Acid
Number: 20090149407
Filed: July 9, 2008
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
The invention "concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic-discovery applications," the patent application's abstract states. "Specifically, the invention relates to small nucleic acid molecules … capable of mediating RNA interference against beta-secretase, amyloid precursor protein, pin-1, presenillin 1, and/or presenillin 2 gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of Alzheimer's disease and any other condition that responds to modulation of BACE, APP, pin-1, PS-1, and/or PS-2 expression or activity."
Title: RNA Interference-Mediated Treatment of Telomerase Gene Expression Using Short Interfering Nucleic Acid
Number: 20090149408
Filed: July 9, 2008
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
The invention, the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating telomerase gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of telomerase gene expression and/or activity by RNA interference using small nucleic acid molecules.
"In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of telomerase genes, such as telomerase template RNA or a telomerase protein," the abstract adds.
Title: siRNA Targeting KRAS
Number: 20090149644
Filed: Dec. 9, 2008
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."